159 related articles for article (PubMed ID: 19406231)
21. Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin.
Songsurang K; Praphairaksit N; Siraleartmukul K; Muangsin N
Arch Pharm Res; 2011 Apr; 34(4):583-92. PubMed ID: 21544723
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery.
Varshosaz J; Hassanzadeh F; Mardani A; Rostami M
Pharm Dev Technol; 2015 Mar; 20(2):183-96. PubMed ID: 24219091
[TBL] [Abstract][Full Text] [Related]
23. Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology.
Li L; Zhao X; Yang C; Hu H; Qiao M; Chen D
Drug Dev Ind Pharm; 2011 Oct; 37(10):1170-80. PubMed ID: 21449822
[TBL] [Abstract][Full Text] [Related]
24. Effects of lipid composition on the properties of doxorubicin-loaded liposomes.
Sakai-Kato K; Nanjo K; Kawanishi T; Okuda H; Goda Y
Ther Deliv; 2015 Jul; 6(7):785-94. PubMed ID: 26228772
[TBL] [Abstract][Full Text] [Related]
25. Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells.
Kuo YC; Liang CT
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):131-7. PubMed ID: 21411296
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation.
Reddy LH; Vivek K; Bakshi N; Murthy RS
Pharm Dev Technol; 2006; 11(2):167-77. PubMed ID: 16749527
[TBL] [Abstract][Full Text] [Related]
27. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles.
Silva AC; Kumar A; Wild W; Ferreira D; Santos D; Forbes B
Int J Pharm; 2012 Oct; 436(1-2):798-805. PubMed ID: 22867992
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery.
Qi J; Yao P; He F; Yu C; Huang C
Int J Pharm; 2010 Jun; 393(1-2):176-84. PubMed ID: 20381598
[TBL] [Abstract][Full Text] [Related]
29. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
Rawat MK; Jain A; Singh S
J Pharm Sci; 2011 Jun; 100(6):2366-78. PubMed ID: 21491449
[TBL] [Abstract][Full Text] [Related]
30. Rifabutin-loaded solid lipid nanoparticles for inhaled antitubercular therapy: Physicochemical and in vitro studies.
Gaspar DP; Faria V; Gonçalves LM; Taboada P; Remuñán-López C; Almeida AJ
Int J Pharm; 2016 Jan; 497(1-2):199-209. PubMed ID: 26656946
[TBL] [Abstract][Full Text] [Related]
31. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
32. Improved Cytotoxic Effect of Doxorubicin by Its Combination with Sclareol in Solid Lipid Nanoparticle Suspension.
Oliveira MS; Lima BHS; Goulart GAC; Mussi SV; Borges GSM; Oréfice RL; Ferreira LAM
J Nanosci Nanotechnol; 2018 Aug; 18(8):5609-5616. PubMed ID: 29458616
[TBL] [Abstract][Full Text] [Related]
33. Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Battaglia L; Gallarate M; Peira E; Chirio D; Muntoni E; Biasibetti E; Capucchio MT; Valazza A; Panciani PP; Lanotte M; Schiffer D; Annovazzi L; Caldera V; Mellai M; Riganti C
J Pharm Sci; 2014 Jul; 103(7):2157-2165. PubMed ID: 24824141
[TBL] [Abstract][Full Text] [Related]
34. Delivery of retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles.
Akanda MH; Rai R; Slipper IJ; Chowdhry BZ; Lamprou D; Getti G; Douroumis D
Int J Pharm; 2015 Sep; 493(1-2):161-71. PubMed ID: 26200751
[TBL] [Abstract][Full Text] [Related]
35. Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.
Siddiqui A; Patwardhan GA; Liu YY; Nazzal S
Int J Pharm; 2010 Nov; 400(1-2):251-9. PubMed ID: 20816930
[TBL] [Abstract][Full Text] [Related]
36. Solid lipid nanoparticles as delivery systems for Gambogenic acid.
Huang X; Chen YJ; Peng DY; Li QL; Wang XS; Wang DL; Chen WD
Colloids Surf B Biointerfaces; 2013 Feb; 102():391-7. PubMed ID: 23010123
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
38. Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system.
Yuan H; Huang LF; Du YZ; Ying XY; You J; Hu FQ; Zeng S
Colloids Surf B Biointerfaces; 2008 Feb; 61(2):132-7. PubMed ID: 17888636
[TBL] [Abstract][Full Text] [Related]
39. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
40. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan.
Kim BD; Na K; Choi HK
Eur J Pharm Sci; 2005 Feb; 24(2-3):199-205. PubMed ID: 15661491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
